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Background:  The  use  of  intradermal  vaccination  or virosomal  vaccines  could  increase  protection  against
inﬂuenza  among  the  vulnerable  population  of  older  adults.  Studies  assessing  the  comparative  effective-
ness  of  these  two inﬂuenza  vaccine  types  in  this  age  group  are  lacking.
Methods:  We  conducted  a retrospective  cohort  study  to  estimate  the comparative  effectiveness  of
intradermal  seasonal  trivalent-inﬂuenza  vaccine  (TIV)  delivered  by a microneedle  injection  system
and  a virosomal-TIV  intramuscularly  delivered  for prevention  of inﬂuenza  hospitalization  in  non-
institutionalized  adults  aged  ≥65  years.  We  obtained  administrative  data  on immunization  status  and
inﬂuenza  hospitalization  for  the  2011–2012  inﬂuenza  season,  and  used  Cox regression  models  to  assess
comparative  effectiveness.  We  estimated  crude  and  adjusted  (age,  sex,  comorbidity,  pharmaceutical
claims,  recent  pneumococcal  vaccination  and  number  of  hospitalizations  for all  causes  other  than
inﬂuenza  between  the previous  and  current  inﬂuenza  seasons)  hazard  ratios  (HR).
Results:  Overall,  164,021  vaccinated  subjects  were  evaluated.  There  were  127  hospitalizations  for
inﬂuenza  among  62,058  subjects,  contributing  914,740  person-weeks  at risk  in the virosomal-TIV  group,
and  133  hospitalizations  for inﬂuenza  among  101,963  subjects,  contributing  1,504,570  person-weeks  at
risk in the  intradermal-TIV  group.  The  crude  HR of  intradermal-TIV  relative  to  virosomal-TIV  was  0.64
(95%  conﬁdence  interval  (CI):  0.50–0.81),  and  the  adjusted  Cox  estimated  HR was  0.67  (95%  CI:  0.52–0.85).
Conclusions:  During  the  2011–2012  inﬂuenza  season  the  risk  of hospitalization  for  inﬂuenza  was  reduced
by  33%  in  non-institutionalized  elderly  adults  who  were  vaccinated  with  intradermal-TIV  compared  with
virosomal-TIV.
ublis© 2014  The  Authors.  PAbbreviations: TIV, trivalent inﬂuenza vaccine; HR, hazards ratio; CI, conﬁdence
nterval; VE, vaccine effectiveness; VHA, Valencia Health Agency; HSA, hospital
ervice area; VAHNSI, Valencia Hospital Network for the Study of Inﬂuenza and
espiratory Virus Diseases; RedMIVA, Microbiological Surveillance Network; CMBD,
inimum set of basic data.
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1. Introduction
Most of the serious morbidity and mortality associated with sea-
sonal inﬂuenza occur in people 65 and older [1–6]. This increasingly
large part of the population is a priority for inﬂuenza vaccina-
tion, but the current vaccine is less effective in older than younger
adults [7,8]. In response to the demand for new vaccines that
elicit a stronger immune response in older adults, various types of
inﬂuenza trivalent inactivated vaccines (TIVs) are available [9–13].
Inﬂuenza vaccine effectiveness (VE) is a major consideration in the
choice of vaccine, but the relative effectiveness of TIVs in older
adults is not well established. Data from direct comparisons of TIVs
are needed to inform decisions about which vaccine to use.
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
5 accine
a
n
o
[
S
u
s
M
c
a
(
i
f
d
i
l
v
t
e
[
e
o
m
o
u
i
E
s
t
p
R
l
s
S
l
c
u
m
c
i
t
v
i
2
2
2
w
i
t
i
1
p
p
V
O
a
3
h448 J. Puig-Barberà et al. / V
To be used during the 2011–2012 season, three vaccines were
cquired by public tender by the Valencia Autonomous Commu-
ity (Valencia region) government, and centrally distributed to be
ffered free of charge to groups targeted for inﬂuenza vaccination
14]: a split trivalent classical intramuscular vaccine (Gripavac®;
anoﬁ-Pasteur MSD, Lyon, France); a virosomal trivalent sub-
nit vaccine (Inﬂexal-V®, Crucell, Leiden, The Netherlands); and a
plit trivalent intradermal vaccine (Intanza® 15 g, Sanoﬁ-Pasteur
SD, Lyon, France). The intradermal TIV seasonal inﬂuenza vac-
ine delivered by a microneedle injection system (Intanza® 15 g)
nd the virosomal TIV, intramuscularly delivered inﬂuenza vaccine
Inﬂexal® V) were targeted free of charge to adults ≥65. Enhanced
mmune response in the elderly is thought to be achieved dif-
erently by each vaccine type. Intradermal vaccination provides
irect access to the immune system through the dermis, which
s rich in immune cells and highly vascularized with an extensive
ymphatic network [11] while virosomal vaccination induces high
irus-neutralizing antibody titers and primes the cellular arm of
he immune system [15]. Health authorities expressed no prefer-
nce for either vaccine, and both vaccines were widely distributed
14].
Several sources of data can be used to estimate relative TIV
ffectiveness in Valencia region. The Valencia Health Agency (VHA)
perates an extensive network of acute care hospitals and pri-
ary healthcare centers, which provide free medical care to 97%
f the population (approximately 5 million inhabitants) [16]. The
se of health care resources within this network is highly local-
zed, with 24 geographically distinct hospital service areas (HSA).
ach HSA offers all hospital care for residents within the given
ervice area. Nine of these 24 HSAs (48% of the population) par-
icipate in a hospital-based seasonal inﬂuenza active surveillance
rogram (Valencia Hospital Network for the Study of Inﬂuenza and
espiratory Virus Disease/VAHNSI) that has provided clinical and
aboratory data from hospitalizations during each inﬂuenza sea-
on since 2009 [17]. In addition, a passive sentinel Microbiological
urveillance Network of VHA laboratories (RedMIVA) [18] records
aboratory-conﬁrmed inﬂuenza hospitalizations. Clinical, pharma-
eutical, microbiological, and demographic data for each person
nder VHA coverage are routinely stored in the VHA Health Infor-
ation System. These data allowed us to construct a retrospective
ohort of people aged 65 and older who were vaccinated against
nﬂuenza during the 2011–2012 season. Our aim was  to evaluate
he relative effectiveness of intradermal versus virosomal inﬂuenza
accines against laboratory-conﬁrmed inﬂuenza-related hospital-
zations during the 2011–2012 inﬂuenza season.
. Methods
.1. Study population and setting
All community-dwelling adults aged ≥65 years as of 1 October
011, residing in Valencia Autonomous Community, Spain, and
ho were vaccinated against inﬂuenza during the 2011–2012
nﬂuenza season were included in the study.
We  identiﬁed through the minimum set of basic data (CMBD),
he VHA electronic health system with clinical and administrative
nformation on all hospital discharges [19], all admissions between
 October 2011 and 31 March 2012 in the nine VHA hospitals that
articipate in a yearly inﬂuenza active surveillance program (Hos-
ital General de Castellon, Hospital de la Plana, Hospital Arnau de
ilanova, Hospital La Fe, Hospital Dr Pesset, Hospital de Xativa-
ntinyent, Hospital San Juan de Alicante, Hospital General de Elda,
nd Hospital General de Alicante). We  excluded admissions in the
0 days following hospital discharge, duplicate cases (if the patient
ad more than one case admission, only the ﬁrst was included), and 32 (2014) 5447–5454
institutionalized adults. Because of sample size limitations, we also
excluded recipients of the split trivalent non-adjuvanted vaccine
(Gripavac®, Sanoﬁ-Pasteur MSD, Lyon, France).
2.2. Vaccines
The trivalent split intradermal vaccine (Intanza® 15 g, Sanoﬁ-
Pasteur MSD, Lyon, France: batches H81904, H81931, H81902, and
H81922) and the virosomal trivalent subunit vaccine (Inﬂexal-V®,
Crucell, Leiden, The Netherlands; batches 300220701, 300210802,
300214905, 300215802, 300214701, 300213101, 300212501, and
300214601) were licensed and approved for the 2011–2012
inﬂuenza season. Following World Health Organization rec-
ommendations, each vaccine contained the following strains:
A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like,
and B/Brisbane/60/2008-like [20]. The virosomal trivalent subunit
vaccine was  exclusively distributed in four VAHNSI HSAs (Hospi-
tal de Xativa-Ontinyent, Hospital San Juan de Alicante, Hospital
General de Elda, and Hospital General de Alicante), whereas the
trivalent split intradermal vaccine was  exclusively distributed in
ﬁve other VAHNSI HSAs (Hospital General de Castellon, Hospital
de la Plana, Hospital Arnau de Vilanova, Hospital La Fe, and Hos-
pital Dr Pesset) [14]. Vaccination targeted people 65 and older
during the vaccination program (which ran from 1 October 2011
and 30 November 2011) [14]. Individuals were considered immu-
nized if their vaccination record in the Vaccine Information System,
an electronic database that stores vaccination records from both
public and private vaccination facilities, indicated administration
of vaccine at least 15 days prior to the date of hospitalization.
2.3. Outcome
An inﬂuenza-related hospitalization case was deﬁned by at least
one of the following: (1) a main discharge diagnosis for hospital
admission of inﬂuenza (ICD-9-CM: 487–488.89), at least 15 days
following the date of vaccination, between 1 October 2011 and
31 March 2012, or (2) admissions identiﬁed through the VAHNSI
scheme between 3 November 2011 and 31 March 2012, at least 15
days following the date of vaccination, and positive for inﬂuenza by
a real-time PCR assay as previously described [21], or (3) inﬂuenza
positive specimens from patients hospitalized between 1 October
2011 and 31 March 2012 reported to the RedMIVA [18] and hospi-
talized at least 15 days following the date of vaccination.
2.4. Covariates
We  used several VHA information systems to search socio-
demographic and clinical data: (1) the hospital CMBD electronic
records, (2) the Population Information System, which provides an
identiﬁcation number for each person under VHA coverage and reg-
isters demographic characteristics, as well as dates and causes of
VHA discharge, including death, and (3) the pharmaceutical module
GAIA which includes information on pharmacy claims. We  identi-
ﬁed the following variables: age at study entry (1 October 2011),
sex, country of birth (coded as Spain or other), the HSA of patient
residence, seasonal inﬂuenza and pneumococcal vaccination in the
previous 3 years, type of VHA coverage, and total number of hospi-
talizations from 1 October 2010 to 30 June 2012.
The presence and severity of chronic medical conditions was
ascertained based on pharmacy claims from 1 January 2011 to 31
December 2011 for each study subject. In brief, dispensed drugs
from any therapeutic class (anatomical therapeutic chemical (ATC)
classiﬁcation) were identiﬁed using the GAIA pharmaceutical mod-
ule. Drugs from three therapeutic classes were selected according
to their association with risk for inﬂuenza-related hospitalization
in our study population [22]: (1) antithrombotic drugs (ATC: B01),
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espiratory drugs (ATC: R03) or cardiovascular drugs (ATC: C01,
02, C03, C07, C08, C09, C10) alone; (2) antithrombotic drugs (ATC:
01) in combination with cardiovascular drugs (ATC: C01, C02, C03,
07, C08, C09, C10); (3) respiratory drugs (ATC: R03) in combination
ith cardiovascular drugs (ATC: C01, C02, C03, C07, C08, C09, C10);
4) antithrombotic drugs (ATC: B01), respiratory drugs (ATC: R03)
nd cardiovascular drugs (ATC: C01, C02, C03, C07, C08, C09, C10)
n combination. Sporadic dispensations from pharmacy claims, as
eﬁned by <6 packs/year dispensed for each drug class, were not
ncluded in these groups. Data on co-morbidities, as reported by the
eneral practitioner, was available from the Vaccine Information
ystem database.
.5. Statistical analysis
Cohort characteristics were described using proportions. Differ-
nces in the proportions between each vaccine group with regard
o socio-demographic and clinical characteristics were examined
ith the chi square test. Parameters that were not normally dis-
ributed were transformed prior to analysis. A P-value of less than
.05 was considered to indicate statistical signiﬁcance.
164,021 (37.4
≥65 years, vacc
residents within
study HSA
62,058 (37.8%) 
≥65 years of age, 
vaccinated with 
virosomal influenza 
vaccine 
Influenza hospitalizations (n  = 127) 
Rate per 100,000 
13.9 (11.7-16.5) 
438,024 (51
≥65 years, vac
862,308
≥65 years, inha
in Valenc
Fig. 1. Flow-chart of study subjects. Vaccinated patients included in the comparative effe 32 (2014) 5447–5454 5449
Confounding was assessed by analysis of the hazard ratio
(HR) for individuals vaccinated with intradermal-TIV relative to
virosomal-TIV, adjusted for each baseline characteristic separately,
and compared with the unadjusted HR. Biological plausibility
and previous knowledge were taken into account in the assess-
ment of confounding. The presence of possible effect modiﬁers
was explored using interaction terms (likelihood-ratio (LR) test;
P < 0.05). Departure from linearity was assessed using the LR test
(P < 0.05).
Crude and adjusted comparative inﬂuenza vaccine effective-
ness (VE) were estimated by calculating the hazard ratio (HR)
of laboratory-conﬁrmed inﬂuenza hospitalization in one vaccine
group compared with the other vaccine group (intradermal-TIV
versus virosomal-TIV), with conﬁdence intervals by Cox regression
models. Point estimates of vaccine effectiveness were calculated as
(1 − HR) × 100. Departure from proportional hazards assumption
was carried out by observing the curves of the adjusted rates by
exposure on a cumulative hazards graph, and evaluating whether
the HR changed with time by a LR test for interaction. Number of
hospitalizations for all causes other than inﬂuenza between the
previous and current inﬂuenza seasons was  modeled as a ﬁxed or
random effects parameter to account for both, propensities of each
5,593 (1.3%) 
Excluded: 
institutionalized 
16,038 (3.7%) 
Excluded: vaccinated 
with a different vaccine 
%) 
inated, 
 the 9 
 
101,963 (62.2%) 
≥65 years of age, 
vaccinated with an  
intradermal influenza 
vaccine 
Influenza hospitalizations (n  = 133) 
Rate per 100,000 
8.8 (7.5-10.5) 
%) 
cinated 
252,372 (57.6%) 
Excluded:  
residents outside 9 
study HSAs  
 
bitants, 
ia 
ctiveness study. 2011–2012 H3N2 predominant inﬂuenza season. Valencia, Spain.
5 accine
i
p
o
o
s
t
t
i
t
p
s
2
M
i
E
C
R
v
t
T
S
a450 J. Puig-Barberà et al. / V
ndividual to be hospitalized and of his/her assigned hospital to hos-
italize a patient. Sensitivity analyses were carried out by excluding
utliers (i.e. patients with the largest number of hospitalizations
r hospitals with the most extreme hospitalization rates). Analy-
es were restricted to the time period starting the week in which
wo or more positive inﬂuenza hospitalizations were identiﬁed on
wo consecutive weeks (18 December 2011) and ended the week
n which no identiﬁcations were observed for at least two  consecu-
ive previous weeks (31 March 2012). All statistical analyses were
erformed using Stata 12.0 (StataCorp, College Station, TX, USA)
tatistical software.
.6. Ethics
The study was conducted according to Ethical Principles for
edical Research Involving Human Participants of the World Med-
cal Association, the Declaration of Helsinki, and the International
thical Guidelines for Epidemiological Studies. The Ethic Research
ommittee of the Directorate of Public Health and Public Health
esearch Center of Valencia approved the study protocol and pro-
ided the exemption from obtaining individual informed consent
o obtain and merge individual data from the different registries.
able 1
tudy subjects characteristics by vaccine type received during the 2011–2012 inﬂuenza s
Vi
n 
Age groups (in years)
65–69 13
70–74  13
75–79  14
80–84 11
85+  8
Gender
Male  28
Female 34
Comorbidities
No  15
Yes  46
Therapeutic drug classes dispenseda
No drugs dispensed 8
Cardiovascular alone 37
Cardiovascular and antithrombotic in combination 11
Cardiovascular and respiratory in combination 1
Antithrombotic, cardiovascular and respiratory in combination 2
Seasonal vaccination 2010–11
No 7
Yes  54
Recent pneumococcal vaccination
No 61
Yes  
Health insurance/coverage
Public 60
International 
Miscellaneousb
Missing 
All  hospitalizationsc
None 49
One  8
Two  2
Three 
Four  
Five  or more 
a Patients grouped according to drugs dispensed to each individual, from 1 January 20
nd  drugs for obstructive airway diseases drugs and the cardiovascular system) were sele
b Private, without insurance or other.
c Number of hospitalizations of all-causes except for inﬂuenza from October 2010 to Ju 32 (2014) 5447–5454
3. Results
3.1. Description of the cohort
Overall, 438,024 adults aged 65 years and older on 1 October
2011 were vaccinated against inﬂuenza during the 2011–2012
season (51% of the total population ≥65 years old in Valencia
region). We excluded 252,372 who resided outside the nine HSAs
under study, 5593 that were institutionalized, and 16,038 who
had received a different vaccine to those being compared. This
left 164,021 (19% of the total population ≥65 years old in Valen-
cia region) subjects for the analysis (Fig. 1). The cohort mean age
was 76.7 (standard deviation: 7.2) years, and 55.3% were female. A
total of 49.7% of cohort members were recorded as suffering from
“chronic cardio-respiratory conditions” in the Vaccine Information
System database, but only 8% were on chronic cardiovascular and
respiratory medication.
3.2. VaccinesA total of 62,058 (37.8%) people were vaccinated with
virosomal-TIV and 101,963 (62.2%) were vaccinated with
intradermal-TIV (Fig. 1, Table 1). The age and sex distribution
eason.
rosomal (N = 62,058, 37.8%) Intradermal (N = 101,963, 62.2%)
% n %
,553 22.8 21,776 21.4
,790 22.2 22,734 22.3
,399 23.2 23,996 23.5
,488 18.5 18,479 18.1
828 14.2 14,978 14.7
,017 45.2 45,310 44.4
,041 54.9 56,653 55.6
,660 25.2 42,731 41.6
,398 74.8 59,592 58.4
835 14.2 13,881 13.9
,532 60.5 61,903 60.6
,883 19.2 20,191 19.8
631 2.6 2733 2.7
177 3.5 3255 3.2
557 12.2 13,304 13.1
,501 87.8 88,659 87.0
,162 98.6 100,416 98.5
896 1.4 1547 1.5
,370 97.3 100,381 98.5
887 1.4 641 0.6
756 1.2 888 0.9
45 0.1 53 0.1
,128 79.2 82,598 81.0
618 13.9 13,084 12.8
619 4.2 3896 3.8
965 1.6 1360 1.3
396 0.6 563 0.6
332 0.5 462 0.5
11 to 31 December 2011. Drugs from 3 therapeutic classes (antithrombotic drugs
cted through codes of the anatomical therapeutic chemical classiﬁcation.
ne 2012.
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f patients vaccinated with each vaccine were similar (Table 1).
ubjects vaccinated with virosomal-TIV were more likely to be
eported as belonging to the “cardio-respiratory risk group” (59.3%
or virosomal versus 43.8% for intradermal TIV; P < .001). However,
harmaceutical claim distributions were similar between both
roups of vaccinees (Table 1).
.3. Laboratory conﬁrmed inﬂuenza hospitalizations
During the time inﬂuenza was circulating in the community,
e identiﬁed 127 hospitalizations related to inﬂuenza among
ubjects vaccinated with virosomal-TIV, out of 914,740 total
erson-weeks at risk. We  also identiﬁed 133 hospitalizations
elated to inﬂuenza among subjects vaccinated with intradermal-
IV, out of 1,504,570 total person-weeks at risk (Fig. 1, Table 2).
rom the total of 260 cases, 241 were identiﬁed through the
AHNSI scheme, 12 were reported to the Microbiological Surveil-
ance Network (RedMIVA) and 15 (0.6%) patients were ascertained
rom the CMBD because of a discharge diagnosis for inﬂuenza
ICD9-CM 487–488.89), seven of these (ﬁve virosomal-TIV and
wo intradermal-TIV vaccinees) lacked a laboratory result for
he conﬁrmation of inﬂuenza virus infection. The most frequent
able 2
nﬂuenza-hospitalization rates and relative risk (RR) of inﬂuenza-related hospitalization 
Virosomal-TIV 
Person-weeks Inﬂuenza-related
admissions (n)
Ratesa
All cohort subjects 914,740 127 13.9
Age  groups (in years) 
65–69  200,780 12 6.0 
70–74 204,140 18 8.8 
75–79 212,540 33 15.5 
80–84 168,990 34 20.1 
≥85  128,280 30 23.4 
Gender 
Male 412,560 74 17.9 
Female 502,180 53 10.6 
Comorbidities 
No  231,470 20 8.6 
Yes  683,270 107 15.7 
Therapeutic drug classes dispensed 
No  drugs dispensed 130,510 5 3.8 
Cardiovascular drugs alone 553,970 64 11.6 
Cardiovascular and antithrombotic
in combination
174,570 31 17.8 
Cardiovascular and respiratory in
combination
23,990 10 41.7 
Antithrombotic, cardiovascular
and respiratory in combination
31,700 17 53.6 
Seasonal vaccination 2010–11 
No  110,970 12 10.8 
Yes  1,430,750 115 14.3 
Recent pneumococcal vaccination 
No  901,700 124 13.8 
Yes  13,040 3 23.0 
Health insurance/coverage 
Public  889,810 127 14.3 
International 13,070 0 - 
Miscellaneousc 11,230 0 - 
Hospitalizationsd
None  727,650 31 4.3 
One  125,480 55 43.8 
Two  37,700 22 58.3 
Three 13,670 11 80.5 
Four  5560 4 72.0 
Five  or more 4680 4 85.5 
a Rates per 100,000 person-weeks.
b Maximum likelihood estimate of the rate ratio (RR; virosomal versus intradermal vac
o-variable categories. CI: conﬁdence interval.
c Private, without insurance or other.
d Number of hospitalizations of all-causes except for inﬂuenza from October 2010 to Ju 32 (2014) 5447–5454 5451
primary diagnosis among those with a positive laboratory result
for inﬂuenza was  chronic obstructive pulmonary disease (COPD)
(24.5%), followed by pneumonia (21.3%). A total of 24.9% of patients
with a positive PCR result for inﬂuenza had a discharge pri-
mary diagnosis corresponding to other diseases of the respiratory
system. COPD and pneumonia were more commonly reported
among patients vaccinated with intradermal-TIV compared with
virosomal TIV (Supplementary Table 1). There was no signiﬁcant
difference between vaccine groups in the mean duration of hospi-
talization (P = 0.254).
Supplementary Table 1 related to this article can be found, in the
online version, at http://dx.doi.org/10.1016/j.vaccine.2014.07.095.
Regardless of the vaccine type, rates of inﬂuenza-related hos-
pitalization increased with age and were higher among males,
subjects who were dispensed a combination of cardiovascular,
antithrombotic and obstructive pulmonary drugs during 2011 and
subjects who  had received at least one dose of the pneumococcal
vaccine in the previous 3 years (Table 2).There were differences in hospitalization with inﬂuenza rates
among HSAs. In particular, one HAS (Hospital General de Elda)
showed higher hospitalization rates than the other eight areas
(Fig. 2).
by type of vaccine.
Intradermal-TIV Crude RR (95% CI)b P-value
Person-weeks Inﬂuenza-related
admissions (n)
Ratesa
1,504,570 133 8.8 0.64 (0.50–0.81) 0.0002
0.63 (0.50–0.81) 0.0002
322,480 6 1.9 0.31 (0.12–0.83)
336,570 20 5.9 0.67 (0.36–1.27)
354,720 37 10.4 0.67 (0.42–1.07)
272,340 35 12.9 0.64 (0.40–1.02)
218,460 35 16.0 0.68 (0.42–1.14)
0.64 (0.50–0.82) 0.0003
667,740 85 12.7 0.71 (0.52–0.97)
836,840 48 5.7 0.54 (0.37–0.80)
0.67 (0.52–0.86) 0.0015
625,700 48 7.7 0.89 (0.53–1.50)
878,870 85 9.7 0.62 (0.46–0.82)
0.64 (0.50–0.81) 0.0002
204,900 7 3.4 0.89 (0.28–2.81)
914,100 72 7.9 0.68 (0.49–0.96)
297,740 27 9.1 0.51(0.30–0.85)
40,240 14 34.8 0.84 (0.37–1.88)
47,590 13 27.3 0.51 (0.25–1.05)
0.64 (0.50–0.81) 0.0003
195,350 16 8.2 0.76 (0.36–1.60)
1,309,220 117 8.9 0.62 (0.48–0.81)
0.64 (0.50–0.81) 0.0002
1,481,830 126 8.5 0.62 (0.48–0.79)
22,740 7 30.8 1.34 (0.35–5.17)
0.64 (0.50–0.81) 0.0002
1,481,270 130 8.8 0.62 (0.48–0.79)
9410 2 21.2 -
13,110 1 7.6 0.71 (0.05–11.43)
0.67 (0.52–0.85) 0.0011
1,222,990 66 5.4 1.27 (0.83–1.84)
191,380 41 21.4 0.49 (0.33–0.73)
56,280 12 21.3 0.36 (0.18–0.74)
19,360 9 46.5 0.58 (0.24–1.40)
8010 4 50.0 0.69 (0.17–2.76)
6540 1 15.3 0.18 (0.02–1.59)
cine), controlling for time from entry and for each co-variable individually and by
ne 2012.
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.4. Comparative inﬂuenza vaccine effectiveness estimates
We  observed a comparative crude inﬂuenza VE of 36% (95% CI,
9–50%) against laboratory-conﬁrmed inﬂuenza hospitalization;
.e., recipients of the intradermal-TIV vaccine showed a 36% reduc-
ion in the risk of inﬂuenza-related hospitalization compared with
ecipients of the virosomal-TIV vaccine (Table 3). This difference in
accine effectiveness was similar after adjustment for age group,
able 3
omparative effectiveness of intradermal and virosomal inﬂuenza vaccines according to 
Conﬁrmation of inﬂuenza hospitalization Virosomal-TIV Intra
N = 62,058 N = 1
n (cases) n (ca
Laboratory and clinical diagnosis (all) 127 133 
Laboratory conﬁrmed cases(discharge code only excluded) 122 131 
Sensitivity analysis
Residents in HAS Hospital General de Elda excluded 81 133 
Subjects with more than 4 hospitalizationsb excluded 123 132 
IV: trivalent inﬂuenza vaccine. HR: hazard ratio. CI: conﬁdence interval. ICD9-CM: Interna
ervice Area.
a Adjusted by age, sex, dispensed drugs, recent pneumococcal vaccination and numbe
urrent  inﬂuenza seasons.
b Subjects with more than 4 hospitalizations for all causes other than inﬂuenza betweef the nine Health Service Areas included in the study.
sex, prescription claims, recent pneumococcal vaccinations (pre-
vious 3 years) and number of hospitalizations for all causes other
than inﬂuenza between the previous and current inﬂuenza seasons
(inﬂuenza VE: 33% (95% CI: 15–48%) (Table 3, Fig. 3).The sensitivity analyses (Table 3) also suggested higher vaccine
effectiveness of the intradermal-TIV versus virosomal-TIV vaccine.
After excluding all residents within Hospital General de Elda HSA
(the HSA that showed higher hospitalization rates than the rest
outcome deﬁnition.
dermal-TIV Intradermal-TIV vs virosomal-TIV
01,963 Crude Adjusteda
ses) HR 95%CI P HR 95%CI P
0.64 0.50–0.81 <0.001 0.67 0.52–0.85 0.001
0.65 0.51–0.84 0.001 0.69 0.54–0.88 0.003
0.75 0.57–0.99 0.042 0.77 0.58–1.01 0.058
0.65 0.51–0.83 0.001 0.68 0.53–0.87 0.002
tional Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation. HSA: Hospital
r of hospitalizations for all causes other than inﬂuenza between the previous and
n the previous and current inﬂuenza seasons.
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easons.
f the hospital areas) the adjusted comparative inﬂuenza VE of
3% (95% CI, −1% to 42%); whereas, when patients with the high-
st number of outside the inﬂuenza season hospitalizations (more
han four) were excluded the adjusted comparative effectiveness
as 32% (95% CI: 13–47%).
. Discussion
In this large retrospective study, we compared the effec-
iveness of intradermal-TIV Intanza® 15 g with virosomal-TIV,
ntramuscularly delivered inﬂuenza vaccine (Inﬂexal® V). Both
accines were administered routinely during the 2011–2012
nﬂuenza season to adults aged ≥65 years. The risk of hospital-
zation for laboratory-conﬁrmed inﬂuenza was  reduced by 33%
n non-institutionalized elderly adults who were vaccinated with
ntradermal-TIV compared with virosomal-TIV.
To our knowledge this is the ﬁrst study to compare the effec-
iveness of intradermal-TIV (Intanza® 15 g) and virosomal-TIV
Inﬂexal® V) vaccines in preventing clinical outcomes in older
dults. We  also report that the intradermal vaccination showed
igniﬁcantly superior effectiveness compared with the virosomal
accination. This observation is in agreement with the ﬁndings
f a recent head-to-head randomized phase IV clinical trial of
ealthy elderly volunteers in which an intradermal-TIV 15 g vac-
ine was associated with consistently higher seroprotection rates
gainst homologous and heterologous strains when compared with
 virosomal-TIV vaccine [23]. Other clinical studies have shown
hat in elderly volunteers the immunogenicity of intradermal-TIV
5 g is comparable with that of an intramuscular subunit vaccine
djuvanted with MF59 [24].Data from clinical trials indicate that intradermal delivery
f inﬂuenza vaccines results in signiﬁcantly enhanced immune
esponses compared with the conventional intramuscular vacci-
ation route [25,26]. This superiority is consistent with the idea proportional hazards regression of admissions with A(H3N2) by vaccine*. *Adjusted
ions for all causes other than inﬂuenza between the previous and current inﬂuenza
of a large number of dendritic cells present in the skin, which act
as potent antigen-presenting cells important in immune surveil-
lance, resulting in a strong humoral and cellular immune responses
[27,28].
Our comparison of two  groups that had both received the sea-
sonal inﬂuenza vaccine overcame confounding by indication. We
derived an accurate indicator of chronic illness based on dispensed
cardiovascular and respiratory medication during 2011, assum-
ing prescription composition and duration as a proxy for chronic
comorbidity [29]. We  were able to ﬁnd a positive laboratory result
for inﬂuenza virus in over 97% of all hospitalizations, 93% were con-
ﬁrmed by PCR, suggesting a high speciﬁcity of the case deﬁnition
in our study.
Most of our study cases (241 out of 260; 93%) were ascer-
tained through active surveillance; therefore, the variability in the
quality of CMBD registers, or the likelihood of specimen sampling
variability for laboratory conﬁrmation of inﬂuenza virus across
hospitals should not have signiﬁcantly affected our results. How-
ever, a potential limitation of our study is that, although the same
study protocol was  used to detect inﬂuenza-like illness (ILI) admis-
sions within 7 days of symptom onset across hospitals, ILI hospital
admission criteria may  vary among hospitals. This could result in
a differential sensitivity to detect the actual number of inﬂuenza-
related hospitalizations across study hospitals. Under this scenario,
it is possible that bias was  introduced by the fact that only one type
of vaccine was  distributed for the catchment area of each hospital,
because the probability of cases going undetected could be asso-
ciated with vaccine type. However, sensitivity analysis excluding
the hospital showing higher admission rates for inﬂuenza-related
hospitalizations did not vary the conclusions of this study.
Our data suggest that intradermal-TIV vaccination performed
using a microinjection system provides higher protection against
inﬂuenza-related hospitalization in elderly adults compared with
the virosomal-TIV, intramuscularly delivered inﬂuenza vaccine in
2011–2012, a season where A(H3N2) dominated [30].
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Concerns about both, A/Perth/16/2009 vaccine strain
atch/mismatch to circulating A(H3N2) strains related to anti-
enic drift in circulating viruses and mutations in the egg-adapted
H3N2 vaccine strain, have been raised to explain the relatively
ow IVE estimates observed in the Northern hemisphere during the
011–2012 season [31–36]. Our study does not include antigenic
nd genetic data of circulating strains so we cannot comment
n suboptimal antigenic match between the 2011–2012 vaccine
nd circulating strains in Valencia. Further studies should be
onducted over several inﬂuenza seasons to assess the variability
f comparative vaccine effectiveness with the degree of antigenic
atch between vaccine and circulating viruses.
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